PhenoPCM

PhenoPCM is a small feasibility study on 20 cancer patients to identify bottlenecks in multimodal molecular profiling of both tissue and blood samples, with the long-term vision to enable molecular profiling for better patient stratification for improved treatment selection.  Tissue biopsy is the gold standard for determining the molecular characteristics of cancer and often only rely on genomic profiling of fixed or frozen tissue. Although this captures vast amounts of information, it provides mainly a single, steady-state snapshot of the disease. We believe, additional levels of molecular information, specifically looking at the phenotype of the disease, such as measuring RNA and protein levels, are needed to fully understand the disease. These measurements provide important information on splice variants, kinase gene-fusions, expressed mutations, and are relevant for neoantigen identification with regards to immunotherapies. PI: MD Dr. Jeff Yachnin.